01—Abstract
Summary
Summary of the 10-K filed February 11, 2022. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported 2021 total revenues of $1.13 billiona (up from $1.05 billion in 2020), driven by net product sales of $1.09 billion.
INGREZZA net product sales were $1.1 billionb for 2021 ($1,081.9 million), up $88.8 million, or 8.9%, from 2020, primarily due to increased total prescriptions. ONGENTYS net product sales were $8.2 million in its first full year after its September 2020 launch. The company was profitable in 2021, with net income of $89.6 million, or $0.92 diluted EPS, compared with $407.3 million in 2020, which included a $296.3 million benefit from releasing most of its deferred tax valuation allowance.
Operating income was $102.5 millionc, versus $163.0 million in 2020, as SG&A rose to $583.3 million from $433.3 million on commercial investment, including the May 2021 launch of the 'TD Spotlight' direct-to-consumer campaign. The company ended 2021 with $1,272.0 million in cash, cash equivalents and marketable securities, and cash provided by operating activities was $256.5 million. Convertible senior notes due 2024 had $381.2 million principal outstanding, and the company stated its existing resources are sufficient for at least the next twelve months.
Two customers accounted for approximately 82% of total product revenue in 2021. Subsequent to year end, on February 8, 2022, the company entered into a lease for a four-building San Diego campus of up to approximately 535,000 gross square feet to serve as its new headquarters. Pipeline milestones include positive top-line KINECT-HD Phase III data for valbenazine in Huntington chorea, with an sNDA planned for the second half of 2022, and a $100.0 milliond upfront payment to Heptares that was expensed as IPR&D.
Generic challengers filed ANDAs against INGREZZA in 2021, and the company sued them in July 2021. Management expects R&D expense and commercial investment to keep rising, and the filing notes material exposure to generic entry and payor pricing pressure.
02—Key points
Key Highlights
- INGREZZA net product sales reached $1.1 billion in 2021 ($1,081.9 million), up $88.8 million, or 8.9%, driven by higher total prescriptions.
- Net income fell to $89.6 million ($0.92 diluted EPS) from $407.3 million in 2020, which benefited from a $296.3 million valuation allowance release.
- Total R&D expense rose to $328.1 million from $275.0 million, and SG&A rose to $583.3 million from $433.3 million.
- Year-end cash, cash equivalents and marketable securities were $1,272.0 million, against $381.2 million of 2.25% convertible senior notes due 2024.
- Two customers represented approximately 82% of total product revenue in 2021.
- Generic filers have challenged INGREZZA patents; the company filed suits in July 2021 in the District of Delaware and the District of New Jersey.
- On February 8, 2022, the company signed a lease for a new San Diego campus of up to approximately 535,000 gross square feet.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2021, Neurocrine Biosciences kept $0.08.
- Revenue$1.13B100.0%
- Cost of revenue−$14.3M1.3%
- Gross profit$1.12B98.7%
- Operating costs−$1.02B89.7%
- Operating income$102.5M9.0%
- Interest, other & tax−$12.9M1.1%
- Net income$89.6M7.9%
Where FY2021 revenue went
$1.13B- SG&A: $583.3M, 51% of revenue
- Other operating costs: $433.4M, 38% of revenue
- Net income: $89.6M, 7.9% of revenue
- Cost of revenue: $14.3M, 1.3% of revenue
- Interest, other & tax: $12.9M, 1.1% of revenue
Kept 7.9% as net incomeNet income $89.6M · 7.9%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 11, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $1.13B$1.05B | +8.4% |
| Cost of Revenue | $14.30M$10.10M | +41.6% |
| Gross Profit | $1.12B$1.04B | +8.1% |
| SG&A Expenses | $583.30M$433.30M | +34.6% |
| Operating Expenses | $1.03B$882.90M | +16.8% |
| Operating Income | $102.50M$163.00M | −37.1% |
| Interest Expense | $25.80M$32.80M | −21.3% |
| Net Income | $89.60M$407.30M | −78.0% |
| EPS (Basic) | $0.95$4.38 | −78.3% |
| EPS (Diluted) | $0.92$4.16 | −77.9% |
| Shares Outstanding (Basic) | 94.60M93.10M | +1.6% |
| Shares Outstanding (Diluted) | 97.90M97.80M | +0.1% |
05—Questions
Frequently Asked Questions
How did Neurocrine's profitability change in 2021?
Net income was $89.6 million, or $0.92 per diluted share, versus $407.3 million in 2020. The 2020 result included a $296.3 million benefit from releasing most of the deferred tax valuation allowance. Operating income declined to $102.5 million from $163.0 million, as operating expenses increased with commercial and R&D investment.
What drove INGREZZA sales growth?
INGREZZA net product sales increased $88.8 million, or 8.9%, to $1.1 billion, primarily driven by increased total prescriptions reflecting higher customer demand and increased commercial activities.
How much debt does the company have and can it fund operations?
$381.2 million of 2.25% convertible senior notes due May 15, 2024 were outstanding at December 31, 2021. The company had $1,272.0 million in cash, cash equivalents and marketable securities and believes existing resources, anticipated INGREZZA sales and investment income will be sufficient for at least the next twelve months.
How concentrated is the company's customer base?
Two customers represented approximately 82% of total product revenue for 2021 and a significant majority of accounts receivable at December 31, 2021. The loss or financial difficulty of either customer could adversely affect revenue and cash flows.
What are the key near-term pipeline catalysts?
The company plans to submit an sNDA for valbenazine in Huntington chorea in the second half of 2022, following positive KINECT-HD Phase III top-line data. Top-line data for essential tremor (NBI-827104) are expected in the middle of 2022, and data for EE-CSWS (NBI-827104) in the second half of 2022. Several other Phase II and III readouts are expected in 2023.
06—Continue